Inactive Instrument

Transgenomic Inc Nasdaq

Equities

US89365K3059

Advanced Medical Equipment & Technology

End-of-day quote Nasdaq Other stock markets
- ^USD	-

14/05	Precipio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
19/04	Precipio, Inc. announced that it expects to receive $0.5 million in funding	CI

Transgenomic : to Present at OneMedForum San Francisco 2015 Conference

January 08, 2015 at 06:33 pm IST

Transgenomic, Inc. (NASDAQ:TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research services, today announced that Chief Executive Officer Paul Kinnon will give a corporate presentation at the 8^th Annual OneMedForum Conference being held at the Marriott Marquis Hotel in San Francisco, CA. Transgenomic will present on Tuesday, January 13, 2015 at 11:10 am PT.

Mr. Kinnon will discuss the company’s commercialization strategy for its Multiplexed ICE COLD-PCR^TM (MX-ICP) technology. MX-ICP is a transformational high sensitivity DNA amplification technology that makes possible the simultaneous detection of known and unknown mutations in multiple genes from either tumor samples or any liquid sample, such as blood or urine.

For more information about the OneMedForum Conference, visit www.onemedconferences.com.

About Transgenomic

Transgenomic, Inc. is a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic technologies, such as its revolutionary ICE COLD-PCR^TM and its unique genetic tests provided through its Patient Testing business. The company also provides specialized clinical and research services to biopharmaceutical companies developing targeted therapies and sells equipment, reagents and other consumables for applications in molecular testing and cytogenetics. Transgenomic’s diagnostic technologies are designed to improve medical diagnoses and patient outcomes.

Latest news about Transgenomic Inc

Precipio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
Precipio, Inc. announced that it expects to receive $0.5 million in funding	19/04	CI
Transcript : Precipio, Inc. - Special Call	02/04
Precipio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	30/03	CI
Precipio, Inc. and Cardinal Health Sign Distribution Agreement for Its HemeScreen®? Portfolio of Molecular Assays for Cancer	06/02	CI
Sector Update: Health Care Stocks Slipping Late Afternoon	18/01	MT
Sector Update: Health Care Stocks Edge Down Wednesday Afternoon	18/01	MT
Precipio Signs Distribution Deal in Japan, Gets First Order; Shares Rise	17/01	MT
Precipio, Inc. Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan	17/01	CI
Precipio, Inc. Announces Board Changes	02/01	CI
Transcript : Precipio, Inc., Q3 2023 Earnings Call, Nov 20, 2023	21/11
North American Morning Briefing : Stocks Futures -2-	20/11	DJ
Precipio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Precipio, Inc. Reports Unaudited Revenue Results for the Third Quarter of 2023	18/23/18	CI
Precipio Says Lower Product Revenue Needed to Achieve Cash Flow Breakeven	25/23/25	MT
Precipio, Inc. Reports Unaudited Revenue Results for the August 2023	13/23/13	CI
Transcript : Precipio, Inc., Q2 2023 Earnings Call, Aug 17, 2023	18/23/18
Precipio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	12/23/12	CI
End in sight for U.S. insider trading case over healthcare leaks	01/23/01	RE
Precipio, Inc. Announces Unaudited Revenue Results for the Second Quarter of 2023	01/23/01	CI
Precipio's Omnia?? Methodology Enables Diagnosis of MDS with Peripheral Blood Instead of Bone Marrow Biopsy	14/23/14	CI
Precipio, Inc. Enters into Collaboration with Prestigious New York-Based Institution to Develop Revolutionary Brain Tumor Panel Using Hemescreen Technology	13/23/13	CI
Precipio Prices $2 Million Registered Direct Offering, Concurrent Private Placement	08/23/08	MT
Precipio, Inc. announced that it expects to receive $0.014343 million in funding	07/23/07	CI
Precipio, Inc.'s Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® Technology	22/23/22	CI

Chart Transgenomic Inc

Duration

Period

More charts

Company Profile

Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses. The Companyâs technologies include HemeScreen and IV-Cell. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its technology enables testing to be completed in one rapid scanning process. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. The Companyâs laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.

Sector

Advanced Medical Equipment & Technology

Calendar

20/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Medical Diagnostic & Testing Equipment

	1st Jan change	Capi.
SARTORIUS AG	-27.34%	1.63TCr
INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD.	+13.44%	178.22Cr
SHANGHAI MICROPORT EP MEDTECH CO., LTD.	-15.91%	141.29Cr
BIOTAGE AB	+37.40%	129.44Cr
REVENIO GROUP OYJ	+5.96%	84Cr
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.	-30.52%	81Cr
CONTEC MEDICAL SYSTEMS CO.,LTD	-38.05%	71Cr
CELLAVISION AB	+27.36%	61Cr
VAREX IMAGING CORPORATION	-26.54%	59Cr

Medical Diagnostic & Testing Equipment